In 2008, the NIDDK initiated the Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study which is prospectively enrolling adults and children with and without acute kidney injury (AKI) at Participating Clinical Centers (PCC). The goals of the study are to define the natural history of AKI;to evaluate the impact of the presence and severity of AKI on renal, cardiovascular and other clinical and patient-centered outcomes;and to identify predictors of adverse events after an episode of AKI. The ASSESS- AKI PCCs represent a broad spectrum of clinical settings ranging from cardiothoracic surgery to intensive care units to general hospital floors in a geographically diverse research consortium. The proposed ASSESS-AKI- Phase 2 will extend follow-up through September 30, 2018. It will offer a unique opportunity to leverage the existing effort and success of ASSESS-AKI-Phase 1 through long-term prospective follow-up of a matched cohort of participants with and without initial AKI for a variety of clinical outcomes that will support addressing novel scientific goals. The enclosed application is in response to RFA-DK-12-509, "Limited Competition for the Continuation of the Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study (U01)," on behalf of the Vanderbilt University Medical Center PCC. The six Specific Aims to be addressed by the participating PCC sites and Data Coordinating Center are:
Aim 1) To re-enroll a high percentage of ASSESS-AKI participants into Phase 2;
Aim 2) To maintain outstanding levels of retention, data quality and outcome ascertainment among ASSESS-AKI participants;
Aim 3) To evaluate the association between AKI and markers of cardiac ischemia, fibrosis, and endothelial dysfunction as potential contributors to excess cardiovascular risk in patients with AKI;
Aim 4) To examine the impact of AKI on the future development of metabolic disturbances among ASSESS-AKI participants;
Aim 5) To employ unbiased proteomic techniques to identify novel urinary protein biomarkers at 3 months after an episode of transient AKI that identify patients at risk for progressive renal dysfunction;
and Aim 6) To promote and support the conduct of ancillary studies in ASSESS-AKI, including collaboration with the broader nephrology research community. Through the ongoing participation of the PCCs, ASSESS-AKI-Phase 2 will become an unparalleled resource that will expand the science related to AKI natural history as well as the impact of AKI on the development and progression of CKD, cardiovascular disease, survival, quality of life, functional status and other important outcomes.

Public Health Relevance

This project is the continuation of the NIDDK-sponsored Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study, which is a prospective cohort study that will enroll approximately 1500 adults and 100 children with and without acute kidney injury (AKI) at Participating Clinical Centers. The overarching goals of this renewal are to re-enroll a high percentage of ASSESS-AKI participants into Phase 2 while maintaining outstanding levels of retention, data quality and outcome ascertainment among ASSESS-AKI participants to complete the goals of Phase 1. We will also evaluate novel associations between AKI and markers of cardiac ischemia, fibrosis, endothelial dysfunction and metabolic and nutritional disturbances among ASSESS-AKI participants and employ unbiased proteomic techniques to identify novel urinary protein biomarkers at 3 months after an episode of transient AKI that identify patients at risk for progressive renal dysfunction.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01DK082192-06S1
Application #
8733102
Study Section
Special Emphasis Panel (ZDK1-GRB-C (M1))
Program Officer
Kimmel, Paul
Project Start
2008-09-11
Project End
2018-06-30
Budget Start
2013-09-19
Budget End
2014-06-30
Support Year
6
Fiscal Year
2013
Total Cost
$50,000
Indirect Cost
$17,949
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Parikh, Chirag R; Butrymowicz, Isabel; Yu, Angela et al. (2014) Urine stability studies for novel biomarkers of acute kidney injury. Am J Kidney Dis 63:567-72
Matheny, Michael E; Peterson, Josh F; Eden, Svetlana K et al. (2014) Laboratory test surveillance following acute kidney injury. PLoS One 9:e103746
Siew, Edward D; Peterson, Josh F; Eden, Svetlana K et al. (2013) Use of multiple imputation method to improve estimation of missing baseline serum creatinine in acute kidney injury research. Clin J Am Soc Nephrol 8:10-8
Siew, Edward D; Peterson, Josh F; Eden, Svetlana K et al. (2012) Outpatient nephrology referral rates after acute kidney injury. J Am Soc Nephrol 23:305-12
Johnson, Ali Cm; Ware, Lorraine B; Himmelfarb, Jonathan et al. (2011) HMG-CoA reductase activation and urinary pellet cholesterol elevations in acute kidney injury. Clin J Am Soc Nephrol 6:2108-13
Siew, Edward D; Ware, Lorraine B; Ikizler, T Alp (2011) Biological markers of acute kidney injury. J Am Soc Nephrol 22:810-20
Ware, Lorraine B; Johnson, Ali C M; Zager, Richard A (2011) Renal cortical albumin gene induction and urinary albumin excretion in response to acute kidney injury. Am J Physiol Renal Physiol 300:F628-38
Siew, Edward D; Matheny, Michael E; Ikizler, T Alp et al. (2010) Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. Kidney Int 77:536-42
Go, Alan S; Parikh, Chirag R; Ikizler, T Alp et al. (2010) The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. BMC Nephrol 11:22
Hung, Adriana M; Crawford, Dana C; Griffin, Marie R et al. (2010) CRP polymorphisms and progression of chronic kidney disease in African Americans. Clin J Am Soc Nephrol 5:24-33